These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34920217)

  • 1. Key considerations for the implementation of clinically focused Prescription Drug Monitoring Programs to avoid unintended consequences.
    Haines S; Savic M; Nielsen S; Carter A
    Int J Drug Policy; 2022 Mar; 101():103549. PubMed ID: 34920217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline.
    Haines S; Lam A; Savic M; Carter A
    Int J Drug Policy; 2022 Nov; 109():103847. PubMed ID: 36067724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
    Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
    Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
    Manders L; Abd-Elsayed A
    Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis.
    Picco L; Lam T; Haines S; Nielsen S
    Drug Alcohol Depend; 2021 Nov; 228():109090. PubMed ID: 34600255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.
    Gunadi C; Shi Y
    BMC Public Health; 2023 Jul; 23(1):1326. PubMed ID: 37434122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment.
    Picco L; Sanfilippo P; Xia T; Lam T; Nielsen S
    Int J Drug Policy; 2022 Nov; 109():103856. PubMed ID: 36150356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees.
    Liang D; Guo H; Shi Y
    Subst Abus; 2021; 42(3):294-301. PubMed ID: 31697195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
    Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
    Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions.
    Islam MM; McRae IS
    BMC Pharmacol Toxicol; 2014 Aug; 15():46. PubMed ID: 25127880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.
    Smith N; Martins SS; Kim J; Rivera-Aguirre A; Fink DS; Castillo-Carniglia A; Henry SG; Mooney SJ; Marshall BDL; Davis C; Cerdá M
    Addiction; 2019 Feb; 114(2):248-258. PubMed ID: 30207015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
    Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
    J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids.
    Liang D; Shi Y
    Drug Alcohol Rev; 2019 Jul; 38(5):494-502. PubMed ID: 31317593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Integrating Access to a Prescription Drug Monitoring Program Within the Electronic Health Record on the Frequency of Queries by Primary Care Clinicians: A Cluster Randomized Clinical Trial.
    Neprash HT; Vock DM; Hanson A; Elert B; Short S; Karaca-Mandic P; Rothman AJ; Melton GB; Satin D; Markowitz R; Golberstein E
    JAMA Health Forum; 2022 Jun; 3(6):e221852. PubMed ID: 35977248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
    Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
    J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Emergency Department Opioid Prescribing Behaviors After Education About Mandated Use of the Pennsylvania Prescription Drug Monitoring Program.
    Martello J; Cassidy B; Mitchell A
    J Addict Nurs; 2018; 29(3):196-202. PubMed ID: 30180006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.